VIVELLE-DOT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIVELLE-DOT (VIVELLE-DOT).
Estradiol replacement therapy; binds to estrogen receptors (ERα and ERβ) to regulate gene transcription, exerting effects on tissues including breast, endometrium, bone, and cardiovascular system.
| Metabolism | Metabolized primarily in the liver via CYP3A4; undergoes enterohepatic recirculation. Major metabolites include estrone and estriol, which are conjugated (glucuronide and sulfate) and excreted in urine. |
| Excretion | Primarily renal (estrogen metabolites, as glucuronide and sulfate conjugates), 90-95% of absorbed dose excreted in urine; <5% in feces via biliary elimination. |
| Half-life | Terminal half-life of estradiol is approximately 2-4 hours due to rapid metabolism, but after transdermal administration, the apparent half-life is longer (around 5-10 hours) due to continuous absorption from the depot; clinical dosing every 3.5 days maintains steady-state. |
| Protein binding | Estradiol is bound 97-99% to plasma proteins, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Approximately 1.2 L/kg; indicates extensive distribution into tissues, consistent with lipophilic nature of estradiol. |
| Bioavailability | Transdermal: 5-10% of the delivered dose is absorbed systemically (actual bioavailability depends on patch formulation and site); oral estradiol bioavailability is ~5% due to extensive first-pass metabolism, but transdermal route avoids first-pass effect. |
| Onset of Action | Transdermal: Estradiol levels reach therapeutic range within 2-4 hours of application; clinical effect (e.g., vasomotor symptom relief) begins within 1-2 weeks. |
| Duration of Action | Each patch provides sustained release of estradiol for approximately 3.5 days (84 hours); recommended twice-weekly application; clinical effects persist with continuous use. |
| Molecular Weight | 272.38 |
Transdermal: 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, or 0.1 mg/day applied twice weekly (every 3-4 days).
| Dosage form | SYSTEM |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution in severe renal disease due to potential accumulation of excipients. |
| Liver impairment | Contraindicated in patients with impaired liver function or active liver disease; no dose recommendations for Child-Pugh classes. |
| Pediatric use | Not indicated for pediatric use; safety and efficacy not established in children. |
| Geriatric use | Initiate at lowest effective dose (0.025 mg/day) and titrate cautiously; increased risk of cardiovascular and thromboembolic events. |
| 1st trimester | Estradiol is contraindicated in pregnancy. Use is associated with fetal harm; estrogens may cause urogenital abnormalities and increase risk of spontaneous abortion. |
| 2nd trimester | Contraindicated. Avoid use as estrogens can affect fetal development; potential for adverse effects on reproductive organs. |
| 3rd trimester | Contraindicated. Use near term may cause vaginal adenosis and cervical erosion in female offspring. |
Clinical note
Comprehensive clinical and safety monograph for VIVELLE-DOT (VIVELLE-DOT).
| Placental transfer | Estradiol crosses the placenta; fetal serum concentrations approach maternal levels. |
| Breastfeeding | Estradiol is excreted in human milk in small amounts; may reduce milk production and quality. Use only if clearly needed; monitor infant for gynecomastia or estrogenic effects. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in women with an intact uterus; concomitant progestin therapy is required. Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism) and probable dementia risk increased in women aged 65 years or older. Estrogens should not be used for prevention of cardiovascular disease or dementia.
| Serious Effects |
Undiagnosed abnormal genital bleedingKnown or suspected pregnancyActive or history of breast cancerActive or history of estrogen-dependent neoplasiaActive deep vein thrombosis or pulmonary embolismActive or history of arterial thromboembolic diseaseHypersensitivity to estradiol or any componentHepatic impairment or disease
| Precautions | Risk of endometrial cancer, cardiovascular disorders (stroke, DVT, PE), probable dementia, breast cancer, gallstones, hypercalcemia, fluid retention, and exacerbation of endometriosis. Discontinue if jaundice or visual disturbances occur. Monitor thyroid function in patients on thyroid replacement therapy. |
| Food/Dietary | Grapefruit juice may increase estrogen levels; avoid large amounts. Caffeine may exacerbate estrogen-related side effects; limit intake. No specific required dietary restrictions, but maintain adequate calcium and vitamin D intake for bone health. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Estrogens are contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and limb defects (based on diethylstilbestrol data). Second and third trimester exposure increases risk of fetal harm, including urogenital abnormalities and potential long-term neurodevelopmental effects. |
| Fetal Monitoring | If inadvertent exposure occurs, monitor for fetal growth, amniotic fluid index, and placental sufficiency via ultrasound. Postnatal follow-up for urogenital and neurodevelopmental effects is advised. Liver function tests and blood pressure monitoring in mother. |
| Fertility Effects | Estrogens can inhibit ovulation and impair fertility due to suppression of gonadotropin release. Discontinuation usually restores normal ovulatory function. |
| Clinical Pearls | Apply to clean, dry skin on lower abdomen or buttock; rotate sites weekly. Avoid application on breasts or waistline. If patch falls off, reapply a new patch and continue same schedule. For missed doses, apply as soon as remembered if within 12 hours; otherwise skip and resume next scheduled dose. Monitor for signs of thromboembolism, especially in smokers over 35. Use lowest effective dose for shortest duration. |
| Patient Advice | Apply patch to clean, dry, intact skin on lower abdomen or buttock. Do not apply to breasts or areas with cuts, rashes, or irritation. · Change patch twice weekly (every 3-4 days). Press firmly for 10 seconds to ensure adhesion. · Avoid exposing patch to direct heat (heating pads, sunbathing, hot baths) as it increases estrogen absorption. · If patch falls off, reapply a new patch and continue same schedule. If more than 12 hours late, skip and resume next scheduled dose. · Report symptoms like chest pain, shortness of breath, leg swelling, severe headache, or vision changes immediately. · Smoking increases risk of serious cardiovascular side effects; avoid smoking or discuss risk with doctor. · Do not use if pregnant or breastfeeding. Inform doctor of all medications, including herbs and supplements. · Store patches at room temperature in sealed pouch until use; do not refrigerate. |